Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition

Longeveron on Wednesday said it would explore strategic options after its experimental stem cell therapy failed to meet ​the main goal of a mid-stage trial for a ‌rare infant heart condition.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。